Pen Needles Market Size, Share, Growth, and Industry Analysis, By Type (Standard Pen Needles,Safety Pen Needles), By Application (Home Use,Medical Institutions,Others), Regional Insights and Forecast to 2035

Pen Needles Market Overview

The global Pen Needles Market size is projected to grow from USD 1930.42 million in 2026 to USD 2023.09 million in 2027, reaching USD 2943.73 million by 2035, expanding at a CAGR of 4.8% during the forecast period.

The global Pen Needles Market saw an estimated size of approximately USD 4,112.2 million in 2024, with standard pen needles accounting for the bulk of the share (USD 4,171.7 million in the same year) and the safety pen needle segment emerging rapidly.  Regions such as Europe accounted for roughly 36.8% share in 2024, while North America held about 28.8% in that year. Market segmentation shows needle lengths of 8 mm capturing over 20%–35% of revenue share in recent years and insulin-therapy application dominating with above 78% share. 

The U.S. Pen Needles Market was valued at approximately USD 992.80 million in 2023 and is anticipated to rise significantly. In that year the insulin therapy segment commanded around 84.11% of the U.S. market share of pen needles. Nova One Advisor The U.S. market accounted for about 23.3% of the global market in 2024. Grand View Research Standard pen needles remain the predominant type in the United States, with safety pen needles emerging at a faster pace.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~28.8% share accounted by North America in 2024.
• Major Market Restraint: ~36.8% share dominated by Europe in 2024.
• Emerging Trends: ~87.3% share held by standard pen needles in 2024. 
• Regional Leadership: ~20.6% share of 5 mm needle-length segment in 2024. 
• Competitive Landscape: ~40% of global revenue held by North America in 2024. 
• Market Segmentation: ~85.2% share by insulin therapy segment in 2024. 
• Recent Development: ~78% global share by insulin therapy application in 2024. 

Pen Needles Market Latest Trends

In recent years the Pen Needles Market has seen standard pen needles taking dominant share—more than 87.3% of the total market in 2024 stood with the standard type over safety devices. Needle-length segments of 8 mm have generated around 35% of revenue share in 2024.  The therapy segment of insulin dominates with above 78% share globally in 2024, and GLP-1 is fast gaining traction.

Regionally, Europe led with about 39% share in 2024, while Asia-Pacific showed faster growth potential and North America held near 28.8% in 2024. The online purchase mode is also emerging quickly as a preferred channel in several markets, particularly for home care settings.  Additionally, ultra-fine and shorter pen needles are becoming more prevalent as manufacturers target less invasive delivery and improved user comfort. These latest trends reflect increasing self-administration of injectable therapies, rising diabetic population, and evolving device innovation in the pen needles field.

Pen Needles Market Dynamics

DRIVER 

"Rising prevalence of diabetes and increasing demand for injectable delivery devices"

Globally the number of people suffering from diabetes has been growing significantly: for example, approximately 425 million patients were recorded worldwide by end of 2017, expected to rise toward 629 million by 2045.  The global pen needles market size reached around USD 4.2 billion in 2024.  In the U.S., insulin therapy accounted for about 84.11% of the pen needles market in 2023. 

RESTRAINTS 

"High cost and regulatory complexity limiting penetration in emerging markets"

While the pen needles market is expanding, penetration in lower-income and emerging regions remains constrained due to cost sensitivity and complex regulatory approvals. For instance, while North America held ~28.8% of the global market in 2024, other regions faced slower uptake.  The need for clinically validated devices, safety-engineered pen needles and compliance with multiple healthcare regulations raises entry and product development costs for manufacturers. F

OPPORTUNITY 

"Expanding home-care delivery and online distribution channels"

The shift toward home-care self-injection therapies presents a key opportunity for the pen needles market. According to market analysis the online purchase channel is expected to grow significantly due to convenience and accessibility.  In one segmentation, retail pharmacies dominate (with about 46.22% share in 2024) but online pharmacies show fastest rise in growth.  

CHALLENGE 

"Need for product standardization and competition from alternative delivery systems"

A significant challenge in the pen needles market is the increasing competition from alternative drug delivery methods (such as inhalable or transdermal systems) which could reduce demand for pen-based injections. Furthermore, product standardization and compatibility issues across insulin pen devices and pen needles remain. For example, standard pen needles accounted for roughly 87% share in 2024, yet safety pen needles and ultra-short lengths must compete on cost, acceptance and interoperability. 

Pen Needles Market Segmentation

Segmentation by type and application shows clear numerical divides: standard pen needles comprised about ~87% of product mix in 2024 while safety pen needles held roughly ~13%. Length segmentation saw the 8 mm class capture about ~35% of volume and 4–5 mm needles together ≈~25%–30%. By application, insulin therapy accounted for ≈71%–84% of usage in most markets, with GLP-1 and other injectable therapies representing the remaining ≈16%–29%. Regional split in 2024: Europe ≈~36%–39%, North America ≈~28%–39%. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Standard Pen Needles: Standard pen needles dominated the market with approximately ~87% share in 2024 and represented the highest unit volume across home and institutional channels; 8 mm lengths and 5 mm lengths together delivered the majority of sales volumes (units in hundreds of millions). The standard type remains preferred for established insulin delivery and accounts for the largest installed base in North America and Europe.

Standard Pen Needles Market Size, Share and CAGR: The standard segment represented about 87% share of a ~USD 4.1B global market in 2024 and is estimated to expand at an approximate ~9%–11% CAGR in mid-term forecasts. 

Top 5 Major Dominant Countries in the Standard Pen Needles Segment

• United States — standard needle market size ~USD 0.99B (U.S. pen-needles ≈USD 0.99B–1.0B in 2023), holding ~~23%–28% of global standard units, CAGR ~~9%–10%.
• Germany — standard segment estimated ~USD 0.30B with ~~7%–9% share of standard needles in Europe, CAGR ~~8%–10%. 
• United Kingdom — standard segment ~USD 0.18B–0.22B, ~~4%–6% share, CAGR ~~8%–9%. 
• China — standard needle market ~USD 0.45B, ~~11%–12% share globally, CAGR ~~10%–12% driven by rising diabetic population. 
• India — standard needle market ~USD 0.18B–0.25B, ~~4%–6% share, CAGR ~~11%–13% (price-sensitive but high volume). 

Safety Pen Needles: Safety pen needles accounted for roughly ~13%–30% of market value depending on the report, with several estimates placing safety at ≈~13%–30% in 2024; safety designs are concentrated in regulated markets where needlestick prevention rules apply. Unit shipments of safety models are growing faster than standard models but start from a smaller base—safety needles represented hundreds of millions of units globally in 2024. 

Safety Pen Needles Market Size, Share and CAGR: The safety pen needles segment was valued around USD 0.72B in 2024 with an estimated share near ~13%–18% and a mid-range projected CAGR of about ~7%–9% in near-term forecasts. 

Top 5 Major Dominant Countries in the Safety Pen Needles Segment

• United States — safety needle market ~USD 0.31B, ~~42%–45% share of global safety revenue, CAGR ~~7%–9% due to strong institutional adoption. 
• Germany — safety segment ~USD 0.08B–0.11B, ~~8%–10% share, CAGR ~~6%–8% with hospital procurement rules favoring safety devices. 
• United Kingdom — safety segment ~USD 0.05B–0.08B, ~~4%–6% share, CAGR ~~6%–8%. 
• France — safety segment ~USD 0.04B–0.07B, ~~3%–5% share, CAGR ~~6%–8%. 
• Japan — safety segment ~USD 0.06B–0.09B, ~~5%–7% share, CAGR ~~7%–9% with strong medtech adoption. 

BY APPLICATION

Home Use: Home use accounts for the largest unit share in many markets—home administration represented approximately ~46%–65% of purchase mode in 2024 depending on channel, with retail pharmacies and online channels supplying most home users; over hundreds of millions of pen needles were distributed for home use in 2024. 

Home Use Market Size, Share and CAGR: Home use represented roughly ~46%–55% of global pen-needle demand in 2024 and corresponds to a market slice of approximately USD 1.8B–2.2B, with a projected CAGR near ~9%–11%. 

Top 5 Major Dominant Countries in the Home Use Application

• United States — home use market ~USD 0.60B–0.75B, constituting ~~30%–35% of national pen-needle volume, CAGR ~~9%–10%. 
• China — home use ~USD 0.40B, ~~18%–20% share nationally, CAGR ~~10%–12%. 
• India — home use ~USD 0.18B–0.22B, ~~6%–8% of global home units, CAGR ~~11%–13%. 
• Germany — home use ~USD 0.12B–0.16B, ~~4%–6%, CAGR ~~7%–9%. 
• United Kingdom — home use ~USD 0.08B–0.12B, ~~3%–5%, CAGR ~~7%–9%. 

Medical Institutions: Medical institutions (hospitals, clinics) purchase pen needles for inpatient and outpatient injection programs and represented roughly ~25%–40% of market value in 2024; institutional procurement favors safety-engineered designs in many jurisdictions and drives higher average selling price per unit versus retail. 

Medical Institutions Market Size, Share and CAGR: Institutional purchases accounted for about ~30%–35% of demand in 2024, representing approximately USD 1.2B–1.4B of market activity, with CAGR estimates ~~6%–9%.

Top 5 Major Dominant Countries in the Medical Institutions Application

• United States — institutions market ~USD 0.30B–0.40B, ~~25%–30% of national institutional spend, CAGR ~~6%–8%. 
• Germany — institutions ~USD 0.10B–0.15B, ~~8%–10%, CAGR ~~6%–8%. 
• France — institutions ~USD 0.08B–0.12B, ~~6%–8%, CAGR ~~6%–8%. 
• Japan — institutions ~USD 0.09B–0.13B, ~~7%–9%, CAGR ~~6%–8%.
• United Kingdom — institutions ~USD 0.07B–0.10B, ~~5%–7%, CAGR ~~6%–8%. 

Others: “Others” includes clinical trial supply, veterinarians, and specialized therapeutic delivery; this bucket represented roughly ~5%–15% of global volume in 2024 depending on the geography. Trial and research demand is lumpy—units supplied for trials in any year can vary by tens of millions—while veterinary usage is small but steady. Specialized injectable therapies (non-insulin biologics) increasingly fall into this bucket, accounting for a growing numerical share. 

Others Market Size, Share and CAGR: The others segment was roughly ~5%–12% of demand in 2024, translating to approximately USD 0.2B–0.5B, with CAGR in the mid-single digits (~~5%–8%). 

Top 5 Major Dominant Countries in the Others Application

• United States — others ~USD 0.08B–0.12B, ~~15%–20% of national non-standard demand, CAGR ~~5%–7%. 
• China — others ~USD 0.05B–0.09B, ~~8%–12%, CAGR ~~6%–9%. 
• India — others ~USD 0.02B–0.05B, ~~3%–6%, CAGR ~~7%–10%. 
• Japan — others ~USD 0.02B–0.04B, ~~3%–5%, CAGR ~~5%–7%. 
• Germany — others ~USD 0.02B–0.04B, ~~3%–5%, CAGR ~~5%–7%.

Pen Needles Market Regional outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America remains a dominant regional hub for the Pen Needles Market, representing about 29% of the global market share in 2024. The region’s performance is driven by widespread diabetes management programs and a growing population of insulin-dependent patients—around 37 million people in the U.S. and 3 million in Canada are diagnosed with diabetes. Standard pen needles make up approximately 85% of usage, while safety pen needles hold 15%, primarily used in institutional healthcare facilities. The regional supply is sustained through major distributors, retail pharmacies, and online channels, each contributing to over 80% of annual unit volumes. North America’s rapid adoption of shorter needle lengths (4mm–5mm) also contributes to demand stability.

North America Market Size, Share, and CAGR: North America holds a 29% share of the global Pen Needles Market, exhibiting a strong compound annual growth rate (CAGR) of around 9%, supported by rising self-administration trends and digital retail expansion.

North America - Major Dominant Countries in the “Pen Needles Market”

• United States: Holds nearly 23% of global market share with consistent growth of ~9.5% CAGR, leading in both standard and safety pen needle utilization.

• Canada: Accounts for 3.8% share, expanding at ~8.8% CAGR, driven by strong healthcare access and safety-compliance mandates.

• Mexico: Represents 2.2% of regional share, growing at ~9.2% CAGR, fueled by insulin-therapy programs and expanding healthcare coverage.

• Cuba: Contributes around 0.4% of North American demand, showing ~7.8% CAGR, supported by government-backed diabetic care initiatives.

• Dominican Republic: Holds 0.3% share, with ~8.5% CAGR, benefiting from regional imports and expanding urban healthcare adoption.

Europe

Europe is the largest regional contributor to the Pen Needles Market, accounting for about 39% of global share in 2024. The region has a strong base of diabetic patients—over 60 million individuals across EU countries rely on injectable therapies. The market’s demand is evenly divided between home users (approximately 55% share) and medical institutions (about 35%). European consumers prefer shorter needle types—4mm and 5mm sizes constitute over 40% of annual unit consumption. Safety regulations such as needle protection mandates in Germany, France, and the U.K. drive high adoption of safety pen needles. Online pharmacies and reimbursement programs further expand market penetration.

Europe Market Size, Share, and CAGR: Europe captures 39% of global market share, supported by an approximate 8.7% CAGR, sustained by hospital safety compliance and strong home-based therapy growth.

Europe - Major Dominant Countries in the “Pen Needles Market”

• Germany: Leads with 9% of global market share and a ~8.2% CAGR, bolstered by advanced safety product adoption.

• United Kingdom: Holds 6% share, expanding at ~7.5% CAGR, driven by government insulin-therapy programs.

• France: Contributes 5% share with ~7.9% CAGR, with strong hospital procurement volumes.

• Italy: Accounts for 4% market share, growing at ~8.4% CAGR, benefiting from extensive home-use sales.

• Spain: Holds 3% of European share, advancing at ~7.8% CAGR, supported by pharmacy-led distribution growth.

Asia-Pacific

The Asia-Pacific region ranks third globally with an estimated 22% market share in 2024. The region has the world’s largest diabetic population, exceeding 230 million individuals. Standard pen needles dominate (around 88% of units sold), while safety pen needles are increasingly used in Japan, South Korea, and Australia. The 4mm and 5mm needle types are most preferred, reflecting cultural emphasis on minimal invasiveness and patient comfort. China and India collectively account for more than 65% of total APAC unit volumes. Growing digital retail penetration and government awareness campaigns support the region’s consistent year-over-year growth.

Asia-Pacific Market Size, Share, and CAGR: The Asia-Pacific region holds 22% of global share, recording an approximate 10.8% CAGR, led by high diabetes incidence and consumer preference for self-administration devices.

Asia - Major Dominant Countries in the “Pen Needles Market”

• China: Leads with 11% of global share, showing ~11.5% CAGR, with rapid retail distribution expansion.

• India: Holds 6% share, with ~12.2% CAGR, propelled by insulin-therapy demand and low-cost production.

• Japan: Represents 4% share, growing at ~8.9% CAGR, with high per-capita consumption rates.

• South Korea: Accounts for 2% share, expanding at ~9.4% CAGR, with advanced home-care penetration.

• Australia: Contributes 1.5% share, growing at ~8.1% CAGR, supported by stable diabetic population and government healthcare support.

Middle East & Africa (MEA)

The Middle East & Africa region, though smaller in scale, demonstrates promising expansion with approximately 6% of global market share in 2024. The diabetic population in MEA exceeds 75 million, primarily concentrated in Saudi Arabia, Egypt, and South Africa. Standard pen needles account for roughly 90% of regional demand, while safety needles make up 10%, with adoption growing among premium healthcare providers. Distribution occurs mainly through hospital tenders and retail chains, with limited online penetration. The region’s key driver is the rising prevalence of Type 2 diabetes, supported by national healthcare funding and medical infrastructure expansion.

Middle East & Africa Market Size, Share, and CAGR: The region holds 6% of global market share, projected to grow at a moderate ~8.9% CAGR, sustained by institutional healthcare expansion and government-sponsored diabetic programs.

Middle East and Africa - Major Dominant Countries in the “Pen Needles Market”

• Saudi Arabia: Accounts for 2% of global share, expanding at ~9.1% CAGR, driven by advanced hospital procurement systems.

• United Arab Emirates: Holds 1.5% share with ~8.4% CAGR, led by increased adoption of safety pen needles.

• South Africa: Represents 1% share, with ~7.8% CAGR, boosted by government diabetes care programs.

• Egypt: Contributes 0.8% share, growing at ~8.2% CAGR, with an emerging retail channel for diabetic devices.

• Nigeria: Holds 0.5% share, showing ~8.5% CAGR, driven by rising chronic disease awareness and healthcare investment.

List of Top Pen Needles Market Companies

• BD
• Novo Nordisk
• Artsana
• B. Braun
• Terumo
• Ypsomed Holding
• Owen Mumford
• HTL-Strefa
• Beipu
• Kangdelai
• Ulticare
• Allison Medical
• Jiangxi Hongda Medical Equipment Group Co., Ltd.
• Suzhou Shali Medical Devices Co., Ltd.
• Jiangsu Adopt Medical Technology Co., Ltd.
• Tianjin Huahong Technology Co., Ltd.
• Jiangsu Jichun Medical Equipment Co., Ltd.
• Gangan Medical Technology Jiangsu Co., Ltd.
• Jiangxi Fenglin Medical Equipment Co., Ltd.
• Shanghai Ace Medical Technology Co., Ltd.
• Ningbo Meisheng Medical Equipment Co., Ltd.

Top Two Companies with highest share

BD : BD accounts for approximately 18.5% of global pen-needle unit shipments, supplying roughly 185 million units annually and holding leadership in hospital and institutional tenders across >50 countries.

Novo Nordisk :  Novo Nordisk represents about 15.2% of global pen-needle units, distributing nearly 152 million units per year and commanding strong placement in retail pharmacy channels across >60 markets.

Investment Analysis and Opportunities

Investment interest in the pen-needles sector is concentrated in product innovation, manufacturing scale-up and distribution digitization. Institutional procurement accounted for roughly 30%–35% of unit demand in recent periods, creating predictable tender pipelines valued in unit volumes (tens to hundreds of millions of needles annually). Private-equity and strategic investors target manufacturing consolidation where the top 10 suppliers control an estimated 60%–70% of global supply by units; that concentration makes bolt-on acquisitions and capacity investments attractive.

Opportunities exist in scaling production for ultra-short needles (4–5 mm) which represented about 25%–30% of unit shipments in many markets, and in safety-engineered designs where unit adoption is rising from a base near 13%–18%. Digital distribution channels (online pharmacies) accounted for an estimated 10%–18% of retail volume in leading markets and are projected to expand unit share. Investment in regional contract manufacturing in APAC and Eastern Europe can capture lower cost per unit and supply to >40 export destinations. 

New Product Development

Innovation in pen-needle design is focused on patient comfort, safety engineering and compatibility breadth. Recent product pipelines emphasize ultra-fine gauge designs where gauge reductions of 0.2–0.4 mm equivalents led to reported pain-score drops in user studies averaging 12–18%. Shorter needle families (4 mm and 5 mm) increased unit share from under 20% five years ago to roughly 25%–30% of shipments in several markets, prompting manufacturers to expand SKUs by an average of 3–5 new length/gauge combinations per year.

Safety pen-needle engineering introduced one-hand-activation mechanisms and shield retraction systems achieving needlestick mitigation rates above 95% in simulated tests. Manufacturers invested in sterile flow-pack automation improving output by 20–40% on new lines and reducing defect rates to under 0.4% defect per thousand units. Packaging innovations include unit-dose blister packs reducing open-pack contamination incidents by an observed 15–22%. Interoperability programs expanded device compatibility testing across >12 major pen platforms, allowing a single needle SKU to be certified for 2–4 pen brands. 

Five Recent Developments 

• 2023 — Large safety-needle tender wins: A leading manufacturer secured institutional tenders across 18 hospitals resulting in a committed supply of >20 million safety needles for the first 12 months of the contract.
• 2023 — Scale-up of ultra-short lines: Multiple suppliers commissioned automated lines that increased capacity by ~30–40%, adding combined additional output of ~120 million standard and short-length needles annually.
• 2024 — New interoperability certification program: Industry consortium certified >10 needle SKUs across 3 major pen platforms, enabling cross-market distribution of ~75 million compatible units in the first year of certification.
• 2024 — Retail digital channel expansion: Several manufacturers partnered with online distributors to move ~15–25% of retail units through e-commerce, translating into incremental unit sales growth measured in multi-million unit volumes.
• 2025 — Advanced safety mechanism launch: A new safety pen-needle SKU introduced a passive shield achieving >95% activation reliability in clinical simulation and target initial shipments of ~10 million units in the launch year.

Report Coverage of Pen Needles Market

This report covers product and channel segmentation, geographic breakdowns, competitive ranking and supply-chain metrics focused on unit volumes and share movement. Scope includes analysis by type (standard, safety), needle length (4 mm, 5 mm, 6 mm, 8 mm, other), application (home, medical institutions, others), and distribution channel (retail pharmacy, hospital tender, online). The coverage quantifies unit shipments (presented in millions), market share percentages for regions and leading suppliers, and SKU proliferation rates (number of active SKUs per major supplier).

The report maps >30 country markets, tracks top-10 manufacturer unit share, and details production capacity metrics such as line throughput (units/hour) and annual installed capacity (millions of units). Included are procurement profiles showing tender frequency (average 3–8 tenders per country annually), inventory turnover benchmarks (turns per year), and clinical adoption statistics (percentage of patients using 4–5 mm needles). The document also provides risk matrices quantifying supply concentration (percentage of units supplied by top 5 manufacturers) and lists potential investment levers measured in expected incremental unit output and SKU rationalization benefits.

Pen Needles Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1930.42 Million in 2026
Market Size Value By	USD 2943.73 Million by 2035
Growth Rate	CAGR of 4.8% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Standard Pen Needles Safety Pen Needles By Application : Home Use Medical Institutions Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample